Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of Occlusive and Open Application in a Psoriasis Plaque Test Design, Exemplarily Using Investigations of Mapracorat 0.1% Ointment versus Vehicle and Reference Drugs.
Wigger-Alberti W, Williams R, von Mackensen YL, Hoffman-Wecker M, Grossmann U, Staedtler G, Nkulikiyinka R, Shakery K. Wigger-Alberti W, et al. Among authors: grossmann u. Skin Pharmacol Physiol. 2017;30(2):102-114. doi: 10.1159/000458415. Epub 2017 Apr 14. Skin Pharmacol Physiol. 2017. PMID: 28407625 Free article. Clinical Trial.
Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
Altcheh J, Castro L, Dib JC, Grossmann U, Huang E, Moscatelli G, Pinto Rocha JJ, Ramírez TE; CHICO Study Group. Altcheh J, et al. Among authors: grossmann u. PLoS Negl Trop Dis. 2021 Jan 7;15(1):e0008912. doi: 10.1371/journal.pntd.0008912. eCollection 2021 Jan. PLoS Negl Trop Dis. 2021. PMID: 33412557 Free PMC article. Clinical Trial.
Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE).
Altcheh J, Sierra V, Ramirez T, Pinto Rocha JJ, Grossmann U, Huang E, Moscatelli G, Ding O. Altcheh J, et al. Among authors: grossmann u. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0119322. doi: 10.1128/aac.01193-22. Epub 2023 Mar 28. Antimicrob Agents Chemother. 2023. PMID: 36975790 Free PMC article. Clinical Trial.
ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.
Rivero R, Esteva MI, Huang E, Colmegna L, Altcheh J, Grossmann U, Ruiz AM; CHICO and CHICO SECURE Study Groups. Rivero R, et al. Among authors: grossmann u. PLoS Negl Trop Dis. 2023 Jun 23;17(6):e0011440. doi: 10.1371/journal.pntd.0011440. eCollection 2023 Jun. PLoS Negl Trop Dis. 2023. PMID: 37352322 Free PMC article. Clinical Trial.
Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (-)-[(18)F]Flubatine in humans.
Patt M, Becker GA, Grossmann U, Habermann B, Schildan A, Wilke S, Deuther-Conrad W, Graef S, Fischer S, Smits R, Hoepping A, Wagenknecht G, Steinbach J, Gertz HJ, Hesse S, Schönknecht P, Brust P, Sabri O. Patt M, et al. Among authors: grossmann u. Nucl Med Biol. 2014 Jul;41(6):489-94. doi: 10.1016/j.nucmedbio.2014.03.018. Epub 2014 Mar 29. Nucl Med Biol. 2014. PMID: 24768146
Neuroimaging of the vesicular acetylcholine transporter by a novel 4-[18F]fluoro-benzoyl derivative of 7-hydroxy-6-(4-phenyl-piperidin-1-yl)-octahydro-benzo[1,4]oxazines.
Sorger D, Scheunemann M, Vercouillie J, Grossmann U, Fischer S, Hiller A, Wenzel B, Roghani A, Schliebs R, Steinbach J, Brust P, Sabri O. Sorger D, et al. Among authors: grossmann u. Nucl Med Biol. 2009 Jan;36(1):17-27. doi: 10.1016/j.nucmedbio.2008.10.006. Nucl Med Biol. 2009. PMID: 19181265
29 results